Shanghai Shen Lian Biomedical Corporation Class ASSE: 688098

"Shanghai Shen Lian Biomedical Corporation"Announcement on Voluntary Disclosure of the Achievement of Primary Endpoint in the Phase II Clinical Trial of UB-221 for the Treatment of Chronic Spontaneous Urticaria

· Issued by Shanghai Shen Lian Biomedical Corporation Class A via Shanghai Stock Exchange

Filed with SSE ·

Announcement on Voluntary Disclosure of the Achievement of Primary Endpoint in the Phase II Clinical Trial of UB-221 for the Treatment of Chronic Spontaneous Urticaria

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Company analysis

Earlier from Shanghai Shen Lian Biomedical Corporation Class A

All Shanghai Shen Lian Biomedical Corporation Class A news releases